Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Trial details
- Registry ID
- NCT07228832
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as 5-Fluorouracil; Leucovorin; Oxaliplatin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832 | Summit Therapeutics | Phase 3 | Recruiting | 2028-05-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |